Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Short term Debt (2023 - 2025)

Historic Short term Debt for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $4.5 million.

  • BioLineRx's Short term Debt fell 5439.83% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 5439.83%. This contributed to the annual value of $4.5 million for FY2024, which is 4241.65% up from last year.
  • As of Q3 2025, BioLineRx's Short term Debt stood at $4.5 million, which was down 5439.83% from $4.5 million recorded in Q2 2025.
  • BioLineRx's 5-year Short term Debt high stood at $10.7 million for Q2 2024, and its period low was $2.6 million during Q1 2023.
  • Moreover, its 3-year median value for Short term Debt was $4.5 million (2024), whereas its average is $4.9 million.
  • Per our database at Business Quant, BioLineRx's Short term Debt surged by 24619.88% in 2024 and then tumbled by 5796.73% in 2025.
  • BioLineRx's Short term Debt (Quarter) stood at $3.1 million in 2023, then surged by 42.42% to $4.5 million in 2024, then changed by 0.0% to $4.5 million in 2025.
  • Its Short term Debt was $4.5 million in Q3 2025, compared to $4.5 million in Q2 2025 and $4.7 million in Q1 2025.